Barclays reaffirmed their hold rating on shares of Waters (NYSE:WAT) in a research note issued to investors on Monday morning. Barclays currently has a $202.00 target price on the medical instruments supplier’s stock.

WAT has been the subject of several other reports. Cowen reaffirmed a hold rating and issued a $190.00 target price on shares of Waters in a research report on Friday, November 3rd. Morgan Stanley upgraded shares of Waters from an underweight rating to an equal weight rating and set a $192.00 price target for the company in a research note on Monday, December 4th. Zacks Investment Research upgraded shares of Waters from a hold rating to a buy rating and set a $217.00 price target for the company in a research note on Tuesday, December 26th. Deutsche Bank increased their price target on shares of Waters from $199.00 to $200.00 and gave the stock a hold rating in a research note on Wednesday, October 25th. Finally, Bank of America increased their price target on shares of Waters from $192.00 to $202.00 and gave the stock a neutral rating in a research note on Friday, November 10th. Eleven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Waters presently has an average rating of Hold and a consensus target price of $197.33.

Waters (NYSE:WAT) traded up $4.13 during trading hours on Monday, hitting $208.96. 532,404 shares of the stock traded hands, compared to its average volume of 392,589. Waters has a 12-month low of $136.14 and a 12-month high of $210.08. The company has a debt-to-equity ratio of 0.66, a quick ratio of 5.71 and a current ratio of 6.16. The stock has a market cap of $16,620.00, a PE ratio of 30.82, a price-to-earnings-growth ratio of 2.71 and a beta of 0.82.

Waters (NYSE:WAT) last posted its earnings results on Tuesday, October 24th. The medical instruments supplier reported $1.77 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.74 by $0.03. Waters had a net margin of 24.34% and a return on equity of 23.61%. The firm had revenue of $565.58 million during the quarter, compared to analysts’ expectations of $555.25 million. During the same period last year, the company posted $1.57 EPS. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. equities research analysts expect that Waters will post 7.42 earnings per share for the current fiscal year.

In other Waters news, SVP Elizabeth B. Rae sold 12,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $197.95, for a total transaction of $2,375,400.00. Following the completion of the sale, the senior vice president now directly owns 18,129 shares in the company, valued at approximately $3,588,635.55. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Rohit Khanna sold 26,913 shares of the firm’s stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $197.93, for a total transaction of $5,326,890.09. Following the sale, the senior vice president now owns 13,677 shares of the company’s stock, valued at $2,707,088.61. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,159 shares of company stock valued at $18,412,172. 5.07% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in WAT. Oppenheimer Asset Management Inc. increased its stake in Waters by 0.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 573 shares of the medical instruments supplier’s stock valued at $105,000 after purchasing an additional 2 shares in the last quarter. ETF Managers Group LLC bought a new stake in Waters during the 2nd quarter valued at about $106,000. Intellectus Partners LLC increased its stake in Waters by 4.9% during the 2nd quarter. Intellectus Partners LLC now owns 667 shares of the medical instruments supplier’s stock valued at $123,000 after purchasing an additional 31 shares in the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Waters in the second quarter worth approximately $160,000. Finally, Acrospire Investment Management LLC grew its stake in shares of Waters by 117.4% in the second quarter. Acrospire Investment Management LLC now owns 926 shares of the medical instruments supplier’s stock worth $170,000 after acquiring an additional 500 shares during the period. Institutional investors and hedge funds own 92.12% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/01/09/waters-wat-earns-hold-rating-from-barclays.html.

Waters Company Profile

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.